NEW YORK, Oct 17 – Genomic information company Incyte Genomics reported Tuesday third quarter net losses of $7.6 million, or 12 cents per diluted share, compared with a net loss of $11.1 million, or 20 cents per diluted share, for the same period a year ago, meeting Wall Street expectations.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.